Encompass Health (EHC) Stock Forecast, Price Target & Predictions
EHC Stock Forecast
Encompass Health stock forecast is as follows: an average price target of $97.00 (represents a -3.22% downside from EHC’s last price of $100.23) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
EHC Price Target
The average price target for Encompass Health (EHC) is $97.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $110.00 to $83.00. This represents a potential -3.22% downside from EHC's last price of $100.23.
EHC Analyst Ratings
According to 6 Wall Street analysts, Encompass Health's rating consensus is 'Buy'. The analyst rating breakdown for EHC stock is 1 'Strong Buy' (16.67%), 5 'Buy' (83.33%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Encompass Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 26, 2024 | Ben Hendrix | RBC Capital | $105.00 | $96.75 | 8.53% | 4.76% |
| Sep 25, 2024 | AJ Rice | UBS | $110.00 | $95.26 | 15.47% | 9.75% |
| May 22, 2024 | Frank Morgan | RBC Capital | $95.00 | $85.86 | 10.65% | -5.22% |
| Apr 25, 2024 | Ann Hynes | Mizuho Securities | $95.00 | $82.80 | 14.73% | -5.22% |
| Mar 28, 2024 | Andrew Mok | Barclays | $101.00 | $81.79 | 23.49% | 0.77% |
| May 03, 2022 | - | RBC Capital | $85.00 | $68.24 | 24.56% | -15.20% |
| May 02, 2022 | - | Raymond James | $85.00 | $68.83 | 23.49% | -15.20% |
| Apr 29, 2022 | - | Credit Suisse | $83.00 | $68.46 | 21.24% | -17.19% |
| Apr 29, 2021 | Scott Fidel | Stephens | $100.00 | $84.62 | 18.18% | -0.23% |
The latest Encompass Health stock forecast, released on Sep 26, 2024 by Ben Hendrix from RBC Capital, set a price target of $105.00, which represents a 8.53% increase from the stock price at the time of the forecast ($96.75), and a 4.76% increase from EHC last price ($100.23).
Encompass Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $107.50 | $101.20 |
| Last Closing Price | $100.23 | $100.23 | $100.23 |
| Upside/Downside | -100.00% | 7.25% | 0.97% |
In the current month, the average price target of Encompass Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Encompass Health's last price of $100.23. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | UBS | Buy | Buy | Hold |
| Oct 29, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Oct 29, 2024 | Barclays | Overweight | Overweight | Hold |
| Oct 11, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Oct 10, 2024 | KeyBanc | - | Overweight | Initialise |
| Sep 26, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Sep 25, 2024 | UBS | Buy | Buy | Hold |
| Aug 06, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Aug 06, 2024 | Stephens | Buy | Buy | Hold |
| Jul 10, 2024 | Stephens | Strong Buy | Strong Buy | Hold |
Encompass Health's last stock rating was published by UBS on Oct 29, 2024. The company gave EHC a "Buy" rating, the same as its previous rate.
Encompass Health Financial Forecast
Encompass Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.21B | $1.19B | $1.16B | $1.14B | $1.09B | $1.33B | $1.33B | $1.32B | $1.28B | $1.29B | $1.23B | $1.21B | $1.17B | $1.07B | $1.18B | $1.18B | $1.16B |
| Avg Forecast | $1.63B | $1.58B | $1.53B | $1.56B | $1.50B | $1.47B | $1.42B | $1.43B | $1.38B | $1.33B | $1.30B | $1.27B | $1.24B | $1.20B | $1.16B | $1.14B | $1.12B | $1.06B | $1.34B | $1.33B | $1.31B | $1.31B | $1.27B | $1.23B | $1.21B | $1.18B | $1.05B | $1.20B | $1.18B | $1.15B |
| High Forecast | $1.65B | $1.59B | $1.55B | $1.58B | $1.52B | $1.48B | $1.43B | $1.44B | $1.41B | $1.33B | $1.30B | $1.27B | $1.25B | $1.21B | $1.18B | $1.16B | $1.14B | $1.06B | $1.34B | $1.33B | $1.31B | $1.31B | $1.27B | $1.23B | $1.21B | $1.18B | $1.05B | $1.20B | $1.18B | $1.15B |
| Low Forecast | $1.61B | $1.56B | $1.51B | $1.54B | $1.48B | $1.45B | $1.40B | $1.42B | $1.36B | $1.33B | $1.30B | $1.27B | $1.23B | $1.19B | $1.15B | $1.13B | $1.11B | $1.06B | $1.34B | $1.33B | $1.31B | $1.31B | $1.27B | $1.23B | $1.21B | $1.18B | $1.05B | $1.20B | $1.18B | $1.15B |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 1.01% | 1.01% | 1.02% | 0.99% | 1.01% | 1.01% | 0.98% | 1.01% | 1.00% | 1.01% | 0.99% | 1.02% | 0.99% | 1.01% | 1.01% |
Encompass Health's average Quarter revenue forecast for Dec 23 based on 6 analysts is $1.24B, with a low forecast of $1.23B, and a high forecast of $1.25B. EHC's average Quarter revenue forecast represents a 2.50% increase compared to the company's last Quarter revenue of $1.21B (Sep 23).
Encompass Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $248.20M | $260.10M | $246.50M | $251.70M | $207.60M | $225.60M | $247.40M | $229.00M | $238.90M | $258.00M | $247.10M | $232.50M | $214.80M | $151.80M | $216.10M | $197.80M | $227.30M |
| Avg Forecast | $332.40M | $321.89M | $313.26M | $318.25M | $306.33M | $299.34M | $289.19M | $293.02M | $281.66M | $271.33M | $265.87M | $256.88M | $252.72M | $244.32M | $237.40M | $233.53M | $271.09M | $217.48M | $274.26M | $212.30M | $266.82M | $268.38M | $259.48M | $177.79M | $246.20M | $241.49M | $215.00M | $211.02M | $240.64M | $235.20M |
| High Forecast | $336.32M | $325.68M | $316.96M | $322.00M | $309.94M | $302.88M | $292.61M | $295.07M | $287.83M | $271.39M | $265.87M | $308.26M | $255.70M | $246.81M | $240.20M | $280.23M | $325.31M | $217.48M | $274.26M | $254.76M | $266.82M | $268.38M | $259.48M | $213.35M | $246.20M | $241.49M | $215.00M | $253.22M | $240.64M | $235.20M |
| Low Forecast | $328.25M | $317.86M | $309.35M | $314.27M | $302.50M | $295.60M | $285.58M | $290.97M | $277.55M | $271.27M | $265.87M | $205.51M | $250.68M | $242.57M | $234.44M | $186.82M | $216.87M | $217.48M | $274.26M | $169.84M | $266.82M | $268.38M | $259.48M | $142.23M | $246.20M | $241.49M | $215.00M | $168.81M | $240.64M | $235.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.10% | 1.06% | 0.93% | 0.95% | 0.82% | 1.17% | 0.86% | 0.89% | 0.99% | 1.39% | 0.94% | 0.89% | 0.71% | 1.02% | 0.82% | 0.97% |
6 analysts predict EHC's average Quarter EBITDA for Dec 23 to be $252.72M, with a high of $255.70M and a low of $250.68M. This is 1.82% upper than Encompass Health's previous annual EBITDA (Sep 23) of $248.20M.
Encompass Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $85.30M | $91.40M | $87.70M | $89.40M | $85.50M | $71.30M | $87.50M | $115.70M | $100.00M | $113.30M | $107.30M | $86.00M | $77.70M | $33.50M | $87.00M | $67.60M | $97.60M |
| Avg Forecast | $134.26M | $129.05M | $132.15M | $133.26M | $120.19M | $120.83M | $122.88M | $122.86M | $105.05M | $96.29M | $103.41M | $100.12M | $83.41M | $80.14M | $75.85M | $91.02M | $108.44M | $65.06M | $98.47M | $82.74M | $107.06M | $108.13M | $99.73M | $77.20M | $87.10M | $75.73M | $33.41M | $84.95M | $85.55M | $90.93M |
| High Forecast | $136.32M | $131.03M | $134.17M | $135.31M | $122.04M | $122.68M | $124.76M | $133.18M | $111.23M | $96.33M | $103.42M | $120.15M | $87.43M | $87.42M | $77.02M | $109.22M | $130.12M | $65.06M | $98.47M | $99.29M | $107.06M | $108.13M | $101.44M | $92.64M | $87.10M | $75.73M | $33.41M | $101.94M | $85.55M | $90.93M |
| Low Forecast | $132.08M | $126.96M | $130.00M | $131.10M | $118.24M | $118.87M | $120.88M | $117.70M | $100.93M | $96.24M | $103.41M | $80.10M | $80.39M | $74.93M | $74.62M | $72.82M | $86.75M | $65.06M | $98.47M | $66.20M | $107.06M | $108.13M | $98.02M | $61.76M | $87.10M | $75.73M | $33.41M | $67.96M | $85.55M | $90.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.20% | 0.96% | 0.82% | 1.31% | 0.72% | 1.06% | 1.08% | 0.92% | 1.14% | 1.39% | 0.99% | 1.03% | 1.00% | 1.02% | 0.79% | 1.07% |
Encompass Health's average Quarter net income forecast for Dec 23 is $83.41M, with a range of $80.39M to $87.43M. EHC's average Quarter net income forecast represents a -2.22% decrease compared to the company's last Quarter net income of $85.30M (Sep 23).
Encompass Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $722.60M | $705.90M | $686.20M | $670.30M | $655.90M | $853.40M | $845.30M | $841.60M | $793.80M | $782.60M | $746.00M | $744.30M | $724.30M | $715.20M | $734.90M | $753.10M | $735.10M |
| Avg Forecast | $819.07M | $793.17M | $771.92M | $784.20M | $754.82M | $737.62M | $712.61M | $722.03M | $694.04M | $668.58M | $655.14M | $967.23M | $622.72M | $602.03M | $584.99M | $879.30M | $996.29M | $535.90M | $675.80M | $799.36M | $657.48M | $661.31M | $639.38M | $536.76M | $606.66M | $595.07M | $529.78M | $717.61M | $592.96M | $579.55M |
| High Forecast | $828.74M | $802.52M | $781.03M | $793.46M | $763.73M | $746.32M | $721.02M | $727.08M | $709.24M | $668.74M | $655.14M | $1.16B | $630.07M | $608.18M | $591.89M | $1.06B | $1.20B | $535.90M | $675.80M | $959.23M | $657.48M | $661.31M | $639.38M | $644.11M | $606.66M | $595.07M | $529.78M | $861.13M | $592.96M | $579.55M |
| Low Forecast | $808.84M | $783.25M | $762.27M | $774.40M | $745.39M | $728.40M | $703.70M | $716.99M | $683.91M | $668.43M | $655.14M | $773.78M | $617.70M | $597.72M | $577.68M | $703.44M | $797.04M | $535.90M | $675.80M | $639.49M | $657.48M | $661.31M | $639.38M | $429.40M | $606.66M | $595.07M | $529.78M | $574.09M | $592.96M | $579.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.20% | 1.21% | 0.78% | 0.67% | 1.22% | 1.26% | 1.06% | 1.28% | 1.20% | 1.22% | 1.39% | 1.23% | 1.22% | 1.35% | 1.02% | 1.27% | 1.27% |
Encompass Health's average Quarter SG&A projection for Dec 23 is $622.72M, based on 6 Wall Street analysts, with a range of $617.70M to $630.07M. The forecast indicates a -13.82% fall compared to EHC last annual SG&A of $722.60M (Sep 23).
Encompass Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.85 | $0.91 | $0.88 | $0.89 | $0.86 | $0.72 | $0.88 | $1.17 | $1.01 | $1.14 | $1.08 | $0.87 | $0.78 | $0.34 | $0.88 | $0.69 | $0.99 |
| Avg Forecast | $1.31 | $1.26 | $1.29 | $1.30 | $1.18 | $1.18 | $1.20 | $1.20 | $1.03 | $0.94 | $1.01 | $0.94 | $0.82 | $0.78 | $0.74 | $0.70 | $0.83 | $0.64 | $0.97 | $0.91 | $1.05 | $1.06 | $0.98 | $0.82 | $0.85 | $0.74 | $0.33 | $0.84 | $0.84 | $0.89 |
| High Forecast | $1.33 | $1.28 | $1.31 | $1.32 | $1.19 | $1.20 | $1.22 | $1.30 | $1.09 | $0.94 | $1.01 | $0.94 | $0.86 | $0.86 | $0.75 | $0.72 | $0.84 | $0.64 | $0.97 | $0.91 | $1.05 | $1.06 | $0.99 | $0.82 | $0.85 | $0.74 | $0.33 | $0.84 | $0.84 | $0.89 |
| Low Forecast | $1.29 | $1.24 | $1.27 | $1.28 | $1.16 | $1.16 | $1.18 | $1.15 | $0.99 | $0.94 | $1.01 | $0.94 | $0.79 | $0.73 | $0.73 | $0.69 | $0.82 | $0.64 | $0.97 | $0.91 | $1.05 | $1.06 | $0.96 | $0.82 | $0.85 | $0.74 | $0.33 | $0.84 | $0.84 | $0.89 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.23% | 1.25% | 1.07% | 1.35% | 0.75% | 0.96% | 1.11% | 0.95% | 1.17% | 1.31% | 1.02% | 1.05% | 1.04% | 1.04% | 0.82% | 1.11% |
According to 6 Wall Street analysts, Encompass Health's projected average Quarter EPS for Dec 23 is $0.82, with a low estimate of $0.79 and a high estimate of $0.86. This represents a -3.99% decrease compared to EHC previous annual EPS of $0.85 (Sep 23).
Encompass Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACHC | Acadia Healthcare Company | $42.33 | $82.33 | 94.50% | Buy |
| MODV | ModivCare | $16.28 | $24.50 | 50.49% | Buy |
| EHAB | Enhabit | $7.63 | $10.25 | 34.34% | Hold |
| INNV | InnovAge | $5.90 | $6.80 | 15.25% | Hold |
| SEM | Select Medical | $36.51 | $40.00 | 9.56% | Buy |
| PNTG | Pennant Group | $32.38 | $34.67 | 7.07% | Buy |
| ADUS | Addus HomeCare | $128.96 | $129.40 | 0.34% | Buy |
| EHC | Encompass Health | $100.23 | $97.00 | -3.22% | Buy |
| ENSG | Ensign Group | $153.39 | $148.20 | -3.38% | Buy |
EHC Forecast FAQ
Is Encompass Health a good buy?
Yes, according to 6 Wall Street analysts, Encompass Health (EHC) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of EHC's total ratings.
What is EHC's price target?
Encompass Health (EHC) average price target is $97 with a range of $83 to $110, implying a -3.22% from its last price of $100.23. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Encompass Health stock go up soon?
According to Wall Street analysts' prediction for EHC stock, the company can go down by -3.22% (from the last price of $100.23 to the average price target of $97), up by 9.75% based on the highest stock price target, and down by -17.19% based on the lowest stock price target.
Can Encompass Health stock reach $200?
EHC's average twelve months analyst stock price target of $97 does not support the claim that Encompass Health can reach $200 in the near future.
What are Encompass Health's analysts' financial forecasts?
Encompass Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.81B (high $5.88B, low $5.75B), average EBITDA is $1.19B (high $1.2B, low $1.17B), average net income is $486.77M (high $502.67M, low $475.69M), average SG&A $2.93B (high $2.96B, low $2.89B), and average EPS is $4.76 (high $4.92, low $4.65). EHC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.29B (high $6.37B, low $6.22B), average EBITDA is $1.29B (high $1.3B, low $1.27B), average net income is $528.73M (high $536.84M, low $520.14M), average SG&A $3.17B (high $3.21B, low $3.13B), and average EPS is $5.17 (high $5.25, low $5.09).
Did the EHC's actual financial results beat the analysts' financial forecasts?
Based on Encompass Health's last annual report (Dec 2022), the company's revenue was $4.35B, which missed the average analysts forecast of $4.86B by -10.43%. Apple's EBITDA was $871.5M, missing the average prediction of $975.13M by -10.63%. The company's net income was $271M, missing the average estimation of $354.71M by -23.60%. Apple's SG&A was $2.6B, missing the average forecast of $3.01B by -13.47%. Lastly, the company's EPS was $2.72, missing the average prediction of $3.35 by -18.75%. In terms of the last quarterly report (Sep 2023), Encompass Health's revenue was $1.21B, beating the average analysts' forecast of $1.2B by 0.91%. The company's EBITDA was $248.2M, beating the average prediction of $244.32M by 1.59%. Encompass Health's net income was $85.3M, beating the average estimation of $80.14M by 6.44%. The company's SG&A was $722.6M, beating the average forecast of $602.03M by 20.03%. Lastly, the company's EPS was $0.85, beating the average prediction of $0.784 by 8.40%